Episódios
-
Drs Sandhya Srinivas and Aria F. Olumi discuss barriers to prostate cancer screening, diagnosis and treatment for transgender patients, and ways to provide gender-affirming, wraparound care.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988738). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Prostate Cancer https://emedicine.medscape.com/article/1967731-overview
Prostate Cancer in Transgender Women: What Does a Urologist Need to Know? https://pubmed.ncbi.nlm.nih.gov/34157213/
How Many Adults and Youth Identify as Transgender in the United States? https://williamsinstitute.law.ucla.edu/publications/trans-adults-united-states/
Gender-Affirming Hormone Therapy: An Updated Literature Review With an Eye on the Future https://pubmed.ncbi.nlm.nih.gov/34982475/
Gender Affirming Surgery: A Comprehensive, Systematic Review of All Peer-Reviewed Literature and Methods of Assessing Patient-Centered Outcomes (Part 1: Breast/Chest, Face, and Voice) https://pubmed.ncbi.nlm.nih.gov/33443903/
Gender Affirming Surgery: A Comprehensive, Systematic Review of All Peer-Reviewed Literature and Methods of Assessing Patient-Centered Outcomes (Part 2: Genital Reconstruction) https://pubmed.ncbi.nlm.nih.gov/34914663/
Prostate-Specific Antigen Testing https://emedicine.medscape.com/article/457394-overview
Prostate Cancer Incidence Under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment https://pubmed.ncbi.nlm.nih.gov/32594155/
Consensus on the Treatment and Follow-up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC) https://pubmed.ncbi.nlm.nih.gov/33856891/
Prostate-specific Antigen Screening in Transgender Patients https://pubmed.ncbi.nlm.nih.gov/36344317/
Multiparametric MRI for the Evaluation of Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/35704822/
BRCA2 Gene Mutation and Prostate Cancer Risk. Comprehensive Review and Update https://pubmed.ncbi.nlm.nih.gov/31915789/
PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/36359439/
World Professional Association for Transgender Health (WPATH) https://www.wpath.org/
-
Drs Sandhya Srinivas and Tanya B. Dorff discuss metastatic hormone-sensitive prostate cancer, which patients are the best candidates for doublets vs triplets, and how we pick these patients.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988737). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Prostate Cancer https://emedicine.medscape.com/article/1967731-overview
Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment https://pubmed.ncbi.nlm.nih.gov/37220335/
Triplet or Doublet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Updated Network Meta-Analysis Stratified by Disease Volume https://pubmed.ncbi.nlm.nih.gov/37055323/
PSMA PET in Imaging Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/35155262/
Risks and Cancer Associations of Metachronous and Synchronous Multiple Primary Cancers: a 25-Year Retrospective Study https://pubmed.ncbi.nlm.nih.gov/34556087/
The Promise of Metastasis-Directed Therapy for Oligometastatic Prostate Cancer: Going Beneath the Surface With Molecular Imaging https://pubmed.ncbi.nlm.nih.gov/35058322/
Gleason Score https://www.ncbi.nlm.nih.gov/books/NBK553178/
Luteinizing Hormone-Releasing Hormone (LHRH) Receptor Agonists Vs Antagonists: a Matter of the Receptors? https://pubmed.ncbi.nlm.nih.gov/23418666/
The Role of CYP17A1 in Prostate Cancer Development: Structure, Function, Mechanism of Action, Genetic Variations and Its Inhibition https://pubmed.ncbi.nlm.nih.gov/29372682/
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial https://pubmed.ncbi.nlm.nih.gov/29384722/
Abiraterone for Prostate Cancer Not Previously Treated With Hormone Therapy https://pubmed.ncbi.nlm.nih.gov/28578639/
Abiraterone Plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/28578607/
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP https://pubmed.ncbi.nlm.nih.gov/34928708/
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/35179323/
Abiraterone Plus Prednisone Added to Androgen Deprivation Therapy and Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer (PEACE-1): a Multicentre, Open-Label, Randomised, Phase 3 Study With a 2 × 2 Factorial Design https://pubmed.ncbi.nlm.nih.gov/35405085/
-
Estão a faltar episódios?
-
Drs Sandhya Srinivas and Oliver Sartor discuss the VISION study, new therapies for patients with metastatic castrate-resistant prostate cancer, and PSMA biomarker-based imaging.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988736). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Lutetium-177-PSMA-617 for Metastatic Castration-resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/34161051/
Prostate Cancer Theranostics: PSMA Targeted Therapy https://pubmed.ncbi.nlm.nih.gov/34053583/
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET Imaging in Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/35603510/
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in Prostate Cancer https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients https://pubmed.ncbi.nlm.nih.gov/27765862/
Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression https://pubmed.ncbi.nlm.nih.gov/30425003/
Effect of Radium-223 Dichloride on Symptomatic Skeletal Events in Patients With Castration-resistant Prostate Cancer and Bone Metastases: Results From a Phase 3, Double-blind, Randomised Trial https://pubmed.ncbi.nlm.nih.gov/24836273/
Long-term Follow-up and Outcomes of Retreatment in an Expanded 50-patient Single-center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/31732676/
[177Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients With Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/33581798/
Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomised Open-label Trial https://pubmed.ncbi.nlm.nih.gov/20888992/
[177Lu]Lu-PSMA-617 in PSMA-positive Metastatic Castration-resistant Prostate Cancer: Prior and Concomitant Treatment Subgroup Analyses of the VISION Trial https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.5001
PSMAfore: A Phase 3 Study to Compare 177Lu-PSMA-617 Treatment With a Change in Androgen Receptor Pathway Inhibitor in Taxane-naïve Patients With Metastatic Castration-resistant Prostate Cancer https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.TPS211
-
Drs Sandhya Srinivas and Heather Cheng discuss PARP inhibitors, clinical trials, and germline vs somatic testing for patients with prostate cancer, as well as the optimal time for this testing.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988734). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Germline Testing in Prostate Cancer: When and Who to Test https://pubmed.ncbi.nlm.nih.gov/34669358/
Germline and Somatic Mutations in Prostate Cancer for the Clinician https://pubmed.ncbi.nlm.nih.gov/31085765/
Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair https://pubmed.ncbi.nlm.nih.gov/37207301/
Genome-Wide Association Study of Prostate Cancer-Specific Survival https://pubmed.ncbi.nlm.nih.gov/26307654/
Inherited DNA-Repair Gene Mutations in Men With Metastatic Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/27433846/
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Prostate Cancer https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
PARP Inhibitors in Metastatic Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/37168382/
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration https://pubmed.ncbi.nlm.nih.gov/32795228/
Olaparib for Metastatic Castration-Resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/32343890/
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043
Rucaparib or Physician's Choice in Metastatic Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/36795891/
FDA Approves Olaparib With Abiraterone and Prednisone (or Prednisolone) for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-olaparib-abiraterone-and-prednisone-or-prednisolone-brca-mutated-metastatic-castration
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/36952634/
Talazoparib Plus Enzalutamide in Men With First-line Metastatic Castration-Resistant Prostate Cancer (TALAPRO-2): A Randomised, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/37285865/
-
Drs Sandhya Srinivas and Shilpa Gupta discuss castration-resistant prostate cancer and the sequence, method of therapy, and specific patient populations in which these drugs will be most effective.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988733). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Prostate Cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
Patient-Reported Outcomes Following Enzalutamide or Placebo in Men With Non-Metastatic, Castration-Resistant Prostate Cancer (PROSPER): A Multicentre, Randomised, Double-Blind, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/30770294/
Apalutamide and Overall Survival in Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/32907777/
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/30763142/
Long-term Safety and Tolerability of Darolutamide and Duration of Treatment in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From the ARAMIS Rollover Study. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.6_suppl.147
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial https://pubmed.ncbi.nlm.nih.gov/29384722/
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC (PSMAddition) https://clinicaltrials.gov/ct2/show/NCT04720157
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/31566937/
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval https://pubmed.ncbi.nlm.nih.gov/35553387/
-
Drs Sandhya Srinivas and Rana R. McKay discuss bone health and survivorship, including risk factors and potential side effects with androgen deprivation therapy in patients with prostate cancer.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988732). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Metastases in Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/29661810/
Do Dietary Calcium and Vitamin D Matter in Men With Prostate Cancer? https://pubmed.ncbi.nlm.nih.gov/29765146/
Zoledronic Acid: A Review of Its Use in the Management of Bone Metastases and Hypercalcaemia of Malignancy https://pubmed.ncbi.nlm.nih.gov/12558465/
Denosumab in Osteoporosis https://pubmed.ncbi.nlm.nih.gov/24289327/
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/23863050/
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial https://pubmed.ncbi.nlm.nih.gov/28030702/
The Prevention of Fragility Fractures in Patients With Non-Metastatic Prostate Cancer: A Position Statement by the International Osteoporosis Foundation https://pubmed.ncbi.nlm.nih.gov/29088899/
Decreased Fracture Rate by Mandating Bone Protecting Agents in the EORTC 1333/PEACEIII Trial Combining Ra223 With Enzalutamide Versus Enzalutamide Alone: An Updated Safety Analysis. https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.5002
Addition of Radium-223 to Abiraterone Acetate and Prednisone or Prednisolone in Patients With Castration-Resistant Prostate Cancer and Bone Metastases (ERA 223): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/30738780/
